Sarel Malan

Prof. Sarel Malan

School of Pharmacy, University of the Western Cape
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2005 in Medicinal Research Reviews
Verified
Journal Article
Closed access
PDF file
WGWerner J. Geldenhuys
Werner J. Geldenhuys
SMSarel Malan
Sarel Malan
JBJeffrey R. Bloomquist
Jeffrey R. Bloomquist
AMAlan P. Marchand
Alan P. Marchand
CSCornelis J. Van der Schyf
Cornelis J. Van der Schyf

11 May 2018 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
IDIreen Denya
Ireen Denya
SMSarel Malan
Sarel Malan
JJJacques Joubert
Jacques Joubert
Introduction: Indazoles are heterocyclic moieties rarely found in nature. They are nitrogen containing chemical compounds composed of a pyrazole ring condensed with a benzene ring. Various indazole derivatives have been described with a wide variety of biological activities. This has aroused great interest in the development of novel indazole based therapeutic agents. Areas covered: Forty-two patents published within the last 5 years (2013–2017) describing derivatives with the indazole scaffold and their therapeutic applications were analysed. Expert opinion: The indazole scaffold is of great pharmacological importance as it forms the basic structure of a large number of compounds with potential therapeutic value. Derivatives have been found to possess promising anticancer and anti-inflammatory activity and have also found application in disorders involving protein kinases (aside from cancer) and neurodegeneration. The compounds where mechanism of action is defined can afford new molecules with biological and therapeutic properties.

1 January 2017 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JJJacques Joubert
Jacques Joubert
GFGermaine B. Foka
Germaine B. Foka
BRBenjamin P. Repsold
Benjamin P. Repsold
DODouglas W. Oliver
Douglas W. Oliver
EKErika Kapp
Erika Kapp
SMSarel Malan
Sarel Malan

29 April 2015 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
FZFrank T Zindo
Frank T Zindo
JJJacques Joubert
Jacques Joubert
SMSarel Malan
Sarel Malan
Much progress has been made in designing analogues that can potentially confer neuroprotection against debilitating neurodegenerative disorders, yet the multifactorial pathogenesis of this cluster of diseases remains a stumbling block for the successful design of an 'ultimate' drug. However, with the growing popularity of the "one drug, multiple targets" paradigm, many researchers have successfully synthesized and evaluated drug-like molecules incorporating a propargylamine function that shows potential to serve as multifunctional drugs or multitarget-directed ligands. It is the aim of this review to highlight the reported activities of these propargylamine derivatives and their prospect to serve as drug candidates for the treatment of neurodegenerative disorders.

3 February 2012 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
JJJacques Joubert
Jacques Joubert
WGWerner J. Geldenhuys
Werner J. Geldenhuys
CSCornelis J. Van der Schyf
Cornelis J. Van der Schyf
DODouglas W. Oliver
Douglas W. Oliver
Gerhardus - Gert Hendrik KrugerGerhardus - Gert Hendrik Kruger
Gerhardus - Gert Hendrik Kruger
SMSarel Malan
Sarel Malan

1 April 2004 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
WGWerner J Geldenhuys
Werner J Geldenhuys
SMSarel Malan
Sarel Malan
TMThangaraju Murugesan
Thangaraju Murugesan
CSCornelis J Van der Schyf
Cornelis J Van der Schyf
JBJeffrey R Bloomquist
Jeffrey R Bloomquist